Chimeric Gαs Subunits for Universal GPCR Ligand Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening G protein-coupled receptors (GPCRs) are complex, expensive, and lack a universal assay for ligand or drug screening due to the specific interactions of GPCRs with different Gα subunits, limiting the ability to identify ligands for various GPCRs effectively.
Innovation Solution
The development of chimeric G proteins, specifically Gαs-based chimeric G proteins with substituted C-terminal amino acids, that promiscuously couple with multiple GPCRs, enabling the use of a cell-based cAMP-dependent reporter gene assay for high-throughput screening of GPCR ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a universal assay is used for screening all GPCRs, then screening efficiency and cost are improved, but the specific interaction requirements between different GPCRs and their coupled Gα subunits cannot be satisfied
Solution Approach 1:
The patent creates a universal screening assay that can screen all GPCRs by engineering chimeric Gα subunits with expanded ligand-binding capabilities. The chimeric Gα subunits incorporate amino acid sequences from multiple native Gα subunits, enabling a single Gα construct to interact with multiple different GPCR types, thus providing universal screening capability across the GPCR family while maintaining specific interaction requirements
Solution Approach 2:
The chimeric Gα subunit acts as an intermediary between diverse GPCRs and the uniform cAMP-dependent detection system. By engineering the Gα subunit to accommodate multiple GPCR types, it mediates the signal transduction from various GPCRs through a common pathway to the cAMP reporter assay, enabling universal screening without sacrificing GPCR-specific interaction fidelity
2Reliability
If multiple specific assays are used for different GPCRs, then GPCR-specific interaction accuracy is maintained, but device complexity and screening cost increase
Solution Approach 1:
The patent employs a single cAMP-dependent reporter gene assay system that can universally detect ligand binding to multiple different GPCR types. The chimeric Gα subunits enable this universal assay to maintain GPCR-specific interaction accuracy by preserving the ability to distinguish between different GPCR-ligand interactions through their coupled signaling pathways, eliminating the need for multiple specialized assays
3Adaptability or versatility
If chimeric Gα subunits with substituted C-terminal amino acids are used, then coupling versatility with multiple GPCRs is improved, but G protein structure complexity increases
Solution Approach 1:
The patent applies local quality by making targeted substitutions only in the C-terminal region of the Gα subunit, which is the specific domain responsible for GPCR interaction. The N-terminal and middle regions of the Gα subunit, which handle other functional aspects like effector coupling and GTP binding, remain unchanged. This localized modification approach increases GPCR coupling versatility while minimizing overall structural complexity changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of GPCR ligands across a wide range of receptors, including those that do not normally couple with Gαs, by increasing the sensitivity and scalability of ligand detection, facilitating the characterization of orphan GPCRs and reducing the complexity and cost of screening processes.
Implementation Method 1
GPCRs transduce signals by catalyzing the dissociation of a coupled heterotrimeric G protein into a GTP-bound Gα subunit and a Gβ/Gγ subunit complex
Implementation Method 2
Activation of the effector adenylyl cyclase by Gαs results in the modulation of the second messenger cyclic adenosine monophosphate (cAMP)
Data Source
AI summary
Abstract of the Disclosure Disclosed herein are methods and compounds for screening and identifying ligands of G protein-coupled receptors (GPCRs). Also disclosed are chimeric G proteins and methods for detecting the activation or inhibition of GPCRs.